Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS

Journal of Mass Spectrometry

Volumn 45, Issue 12, 2010, Pages 1426-1442

  Meyer, Markus R ^a   Du, Peng ^a   Schuster, Frank ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Landeskriminalamt Sachsen   (Germany)

Author keywords

CYP; designer drugs; GC MS; HR MS; MDPV; metabolism; STA

Indexed keywords

CYP; DESIGNER DRUGS; GC-MS; HR-MS; MDPV; STA;

BIOMOLECULES; BODY FLUIDS; CARBOXYLIC ACIDS; DESIGN; EXTRACTION; INTERNET PROTOCOLS; LIQUID CHROMATOGRAPHY; LIVER; METABOLITES;

METABOLISM;

3,4 METHYLENE DIOXYPYROVALERONE; ALPHA PYRROLIDINOPHENONE; CARBOXYLIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLITE; ISOENZYME; LACTAM; PYROVALERONE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DEMETHYLATION; DRUG DESIGN; DRUG DETERMINATION; DRUG METABOLISM; HUMAN; HYDROXYLATION; INCUBATION TEMPERATURE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METHYLATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; RING OPENING; URINALYSIS; URINE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BENZODIOXOLES; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; PYRROLIDINES; RATS; RECOMBINANT PROTEINS;

MUSCOVY DUCK PARVOVIRUS; RATTUS;

EID: 78650716854     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1859     Document Type: Article

References (34)

1. J. Goldberg, G. Gardos, J. O. Cole,. A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int. Pharmacopsychiatr. 1973, 8, 60.
2. H. Heimann, G. Lukacs,. Experimental psychological differentiation of the effect of 2 psychostimulants (F-1983 and amphetamine) in humans. Psychopharmacologia 1965, 8, 79.
3. S. Soderholm, N. M. Viukari, R. Rimon,. The psychotropic effect of the pyrovalerone (F-1983), placebo, the milieu therapy and mental condition of the patients in forensic psychiatry. Nervenarzt 1976, 47, 88.
4. J. P. Fauquet, E. Morel, C. Demarty, J. R. Rapin,. Role of central catecholamines in the psychostimulant activity of pyrovalerone. Arch. Int. Pharmacodyn. Ther. 1976, 224, 325.
5. A. Servin, J. P. Fauquet, C. Jacquot, J. R. Rapin,. Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem. Pharmacol. 1978, 27, 1693.
6. G. Stille, H. Ackermann, E. Eichenberger, H. Lauener,. Comparative pharmacological study of a new central stimulant, 1-p-tolyl-1-oxo-2-pyrrolidino- n-pentane HCl. Arzneim. Forsch. 1963, 13, 871.
7. P. C. Meltzer, D. Butler, J. R. Deschamps, B. K. Madras,. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49, 1420.
8. D. Springer, G. Fritschi, H. H. Maurer,. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 796, 253.
9. D. Springer, F. T. Peters, G. Fritschi, H. H. Maurer,. Studies on the metabolism of the new pyrrolidino-propiophenone designer drugs MPPP and MDPPP. Proceedings of the 39th International TIAFT Meeting in Prague, 2001, M. Balikova, E. Navakova, (Eds). Charles University: Prague, 2002, 122.
10. D. Springer, L. D. Paul, R. F. Staack, T. Kraemer, H. H. Maurer,. Identification of cytochrome P450 enzymes involved in the metabolism of 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes. Xenobiotica 2005, 35, 227.
11. D. Springer, F. T. Peters, G. Fritschi, H. H. Maurer,. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 773, 25.
12. F. T. Peters, M. R. Meyer, G. Fritschi, H. H. Maurer,. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 824, 81.
13. C. Sauer, F. T. Peters, C. Haas, M. R. Meyer, G. Fritschi, H. H. Maurer,. New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2009, 44, 952.
14. M. R. Meyer, J. Wilhelm, F. T. Peters, H. H. Maurer,. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 2010, 397, 1225.
15. F. Westphal, T. Junge, P. Rosner, F. Sonnichsen, F. Schuster,. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with alpha-pyrrolidinophenone structure. Forensic Sci. Int. 2009, 190, 1.
16. H. H. Maurer,. Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control [review]. Clin. Chem. Lab. Med. 2004, 42, 1310.
17. H. H. Maurer,. Hyphenated mass spectrometric techniques - indispensable tools in clinical and forensic toxicology and in doping control [review]. J. Mass Spectrom. 2006, 41, 1399.
18. H. H. Maurer, K. Pfleger, A. A. Weber,. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites. Wiley-VCH: Weinheim, 2007.
19. A. F. McKay, W. L. Ott, G. W. Taylor, M. N. Buchanan, J. F. Crooker,. Diazohydrocarbons. Can. J. Res. 1950, 28, 683.
20. A. H. Ewald, D. Ehlers, H. H. Maurer,. Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 2008, 390, 1837.
21. H. H. Maurer, K. Pfleger, A. A. Weber,. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites. Wiley-VCH: Weinheim, 2011.
22. H. H. Maurer, K. Pfleger, A. A. Weber,. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites. Wiley-VCH: Weinheim, 2007.
23. M. R. Meyer, F. T. Peters, H. H. Maurer,. Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine. Clin. Chem. 2010, 56, 575.
24. F. Westphal, T. Junge, P. Rosner, G. Fritschi, B. Klein, U. Girreser,. Mass spectral and NMR spectral data of two new designer drugs with an alpha-aminophenone structure: 4′-methyl-alpha-pyrrolidinohexanophenone and 4′-methyl-alpha-pyrrolidinobutyrophenone. Forensic Sci. Int. 2007, 169, 32.
25. F. W. McLafferty, F. Turecek,. Interpretation of Mass Spectra. University Science Books: Mill Valley, CA, 1993.
26. R. M. Smith, K. L. Busch,. Understanding Mass Spectra - A Basic Approach. Wiley: New York, NY, 1999.
27. R. A. de-Zeeuw, J. P. Franke, H. H. Maurer, K. Pfleger,. Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and Their Metabolites (Report of the DFG Commission for Clinical Toxicological Analysis, Special Issue of the TIAFT Bulletin). VCH Publishers: Weinheim, 1992.
28. D. Springer, G. Fritschi, H. H. Maurer,. Metabolism and toxicological detection of the new designer drug 4′-methoxy-α- pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 793, 331.
29. H. S. Shin, Y. S. Shin, S. Lee, B. B. Park,. Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J. Anal. Toxicol. 1996, 20, 568.
30. S. Vickers, S. L. Polsky,. The biotransformation of nitrogen containing xenobiotics to lactams. Curr. Drug Metab. 2000, 1, 357.
31. M. R. Meyer, H. H. Maurer,. Enantioselectivity in the methylation of the catecholic phase-I metabolites of methylenedioxy designer drugs and their capability to inhibit COMT catalyzed dopamine 3-methylation. Chem. Res. Toxicol. 2009, 22, 1205.
32. H. H. Maurer, K. Pfleger, A. A. Weber,. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites. Wiley-VCH: Weinheim, 2011.
33. E. Kovats,. Gaschromatographische Charakterisierung organischer Verbindungen. Teil 1. Retentionsindices aliphatischer Halogenide, Alkohole, Aldehyde und Ketone. Helv. Chim. Acta 1958, 41, 1915.
34. DFG. Senatskommission für Klinisch-toxikologische Analytik. J. Clin. Chem. Clin. Biochem. 1982, 20, 699.